AR087501A1 - Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 - Google Patents

Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1

Info

Publication number
AR087501A1
AR087501A1 ARP120102918A ARP120102918A AR087501A1 AR 087501 A1 AR087501 A1 AR 087501A1 AR P120102918 A ARP120102918 A AR P120102918A AR P120102918 A ARP120102918 A AR P120102918A AR 087501 A1 AR087501 A1 AR 087501A1
Authority
AR
Argentina
Prior art keywords
trpa1
receiver
inhibiting compounds
ionic channel
potential transitory
Prior art date
Application number
ARP120102918A
Other languages
English (en)
Inventor
Yugui Gu
Spencer D Kimball
Qingy Li
Blaise S Lippa
Dominic Ryan
Xinyuan Wu
Dong ZOU
Chester A Metcalf Iii
Original Assignee
Hydra Biosciences Inc
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Inc, Cubist Pharm Inc filed Critical Hydra Biosciences Inc
Publication of AR087501A1 publication Critical patent/AR087501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta divulgación describe un compuesto de fórmula (1) (por ejemplo, fórmula (1a)) y composiciones farmacéuticas para inhibir el canal iónico TRPA1 y/o afecciones médicas relacionadas con TRPA1, tal como el dolor.Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables.
ARP120102918A 2011-08-09 2012-08-09 Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 AR087501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521705P 2011-08-09 2011-08-09

Publications (1)

Publication Number Publication Date
AR087501A1 true AR087501A1 (es) 2014-03-26

Family

ID=46717941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102918A AR087501A1 (es) 2011-08-09 2012-08-09 Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1

Country Status (13)

Country Link
US (1) US9193729B2 (es)
EP (1) EP2742048B1 (es)
JP (1) JP2014521724A (es)
KR (1) KR20140073496A (es)
CN (1) CN103265543A (es)
AR (1) AR087501A1 (es)
AU (1) AU2012294300A1 (es)
BR (1) BR112014002960A2 (es)
CA (1) CA2843965A1 (es)
MX (1) MX2014001551A (es)
RU (1) RU2014108885A (es)
TW (1) TW201311690A (es)
WO (1) WO2013023102A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742048B1 (en) 2011-08-09 2016-04-27 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
EP2805718B1 (en) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Heterocyclic amide derivative and pharmaceutical product containing same
WO2014026073A1 (en) * 2012-08-09 2014-02-13 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
SI2970303T1 (sl) 2013-03-15 2017-08-31 Hydra Biosciences, Inc. Substituirani ksantini in njihove metode uporabe
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
CA2961412C (en) 2014-09-19 2024-01-16 Hydra Biosciences, Inc. Inhibiting the transient receptor potential a1 ion channel
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
EP3554500A1 (en) 2016-12-16 2019-10-23 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
EP4233871A3 (en) 2018-01-31 2023-11-01 Eli Lilly and Company Inhibiting the transient receptor potential a1 ion channel
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059107A2 (en) 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
US20070016283A1 (en) 2005-06-28 2007-01-18 Stout Medical Group, Inc. Micro-thin film structures for cardiovascular indications
DE102005054610B4 (de) 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
DK2170309T3 (en) * 2007-06-22 2017-01-09 Hydra Biosciences Inc Dioxo-2,6, -2,3-dihydro-1H-purine compounds useful in the treatment of diseases related to activity of TRPA1 channel
WO2009144548A1 (en) 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2009152261A1 (en) 2008-06-10 2009-12-17 Brandeis University Methods of insect control by inhibiting or modulating the trpa1 ion gated channel or family members
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
TW201026700A (en) 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
SI2411393T1 (sl) 2009-03-23 2014-03-31 Glenmark Pharmaceuticals S.A. Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji
WO2010138879A1 (en) * 2009-05-29 2010-12-02 Hydra Biosciences, Inc. Compounds useful for treating disorders related to trpa1
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
WO2011043954A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Novel trpa1 antagonists
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
JP5847827B2 (ja) 2010-10-12 2016-01-27 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｔｒｐａ１受容体アンタゴニスト
CA2820448A1 (en) 2010-12-20 2012-06-28 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
BR112013032025A2 (pt) 2011-06-13 2016-12-20 Glenmark Pharmaceutical S A antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação
EP2742048B1 (en) 2011-08-09 2016-04-27 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
US20140158116A1 (en) 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Inhibiting trpa1 for the treatment of asthma
WO2014026073A1 (en) 2012-08-09 2014-02-13 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel

Also Published As

Publication number Publication date
TW201311690A (zh) 2013-03-16
MX2014001551A (es) 2014-09-15
EP2742048A1 (en) 2014-06-18
US9193729B2 (en) 2015-11-24
EP2742048B1 (en) 2016-04-27
WO2013023102A1 (en) 2013-02-14
US20130274273A1 (en) 2013-10-17
JP2014521724A (ja) 2014-08-28
KR20140073496A (ko) 2014-06-16
BR112014002960A2 (pt) 2017-02-21
RU2014108885A (ru) 2015-09-20
CN103265543A (zh) 2013-08-28
AU2012294300A1 (en) 2014-03-20
CA2843965A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
AR087501A1 (es) Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CR20150371A (es) Inhibidores de prmt5 y sus usos
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
PH12015501710A1 (en) Combination formulation of two antiviral compounds
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
NZ716840A (en) Combination formulation of two antiviral compounds
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MY187718A (en) Pharmaceutical formulations
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
MX362879B (es) Usos novedosos.
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
JOP20200030A1 (ar) مركب خماسي الحلقة

Legal Events

Date Code Title Description
FB Suspension of granting procedure